Post by Sachs Associates

📊🤝 #Sachs_OCIF – Where are the markets and Dealmaking heading in cardiometabolic health? Join us for the State of the Markets & BioPharma Dealmaking Panel at the 2nd Annual Obesity & Cardiometabolic Innovation Forum, taking place June 5, 2026 at the Royal Sonesta New Orleans. This key session will explore the current market landscape, investment trends, and Dealmaking activity across obesity, diabetes, and cardiometabolic diseases. Hear from industry leaders and investors on capital flows, partnership strategies, and what to expect next in one of the fastest-growing sectors in biopharma. 🎤 Co-Chaired by: Christopher Stern, Ph.D., Managing Director & Partner, L.E.K. Consulting Steven Dickman, CEO, CBT Advisors 👥 Panellists: David Kendall, Chief Medical Officer, Zealand Pharma A/S David Risinger, Senior Managing Director, Diversified Biopharmaceuticals Research, Leerink Partners LLC Lauren Cujé, Managing Director, New Ventures, RTW Investments, LP Melissa Ann Jones, PhD, Director, Metabolic Disorders, Foundation for the National Institutes of Health (FNIH) 🎟️ Learn more and register: www.sachsforum.com/2ocif Join us in person or online ahead of ADA 2026. #BioPharmaDeals #LifeSciencesInvestment #ObesityInnovation #CardiometabolicHealth #BiotechInvestment #PharmaStrategy #BiotechConference